Tamoxifen Inhibits Inward Rectifier K+ 2.x Family of Inward Rectifier Channels by Interfering with Phosphatidylinositol 4,5-Bisphosphate-Channel Interactions

Tamoxifen, an estrogen receptor antagonist used in the treatment of breast cancer, inhibits the inward rectifier potassium current (I K1 ) in cardiac myocytes by an unknown mechanism. We characterized the inhibitory effects of tamoxifen on Kir2.1, Kir2.2, and Kir2.3 potassium channels that underlie...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of pharmacology and experimental therapeutics 2009-11, Vol.331 (2), p.563-573
Hauptverfasser:	Daniela Ponce-Balbuena, AngÃ©lica LÃ³pez-Izquierdo, Tania Ferrer, Aldo A. RodrÃguez-Menchaca, IvÃ¡n A. ArÃ©chiga-Figueroa, JosÃ© A. SÃ¡nchez-Chapula
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Cats Cell Line Chloroquine - pharmacology Electrophysiology Estrogen Antagonists - pharmacology Heart Atria - metabolism Heart Ventricles - metabolism Humans Ion Channel Gating - drug effects Ion Channels - drug effects Ion Channels - metabolism Kinetics Myocytes, Cardiac - drug effects Myocytes, Cardiac - metabolism Patch-Clamp Techniques Phosphatidylinositol 4,5-Diphosphate - metabolism Potassium Channel Blockers - pharmacology Potassium Channels, Inwardly Rectifying - antagonists & inhibitors Potassium Channels, Inwardly Rectifying - genetics Raloxifene Hydrochloride - pharmacology Tamoxifen - pharmacology Transfection
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!